research When two plus two must not equal four
Regulatory challenges make developing combination therapies in urology difficult and costly.
Search
forProducts matching "reliablerxpharmacy"
Tracking 7 products like 176 Hair4u 5%, 177 Hair4u 2%, 178 Hair4u 10%, 179 Tugain 5% 60ml and 180 Coverit 2% 60ml from by companies like ReliableRxpharmacy. View all 7 products »
Sort by
Research
180-210 / 1000+ resultsresearch Pharmacokinetics and Bioequivalence of Finasteride Tablets in Healthy Subjects
The two finasteride tablet formulations are bioequivalent.
research Referee report. For: Recent advances in treatment for Benign Prostatic Hyperplasia [version 1; referees: 2 approved]
BPH treatment improved with personalized medicine, new drugs, and less invasive surgeries.
research Analysis of metabolic characteristics of epristeride in zebrafish based on LC-Q-TOF MS and its potential applications in doping control
Epristeride's metabolism in zebrafish helps improve doping detection methods.
research Rapid determination and quantification of hair-growth compounds in adulterated products by ultra HPLC coupled to quadrupole-orbitrap MS
About 21% of tested hair loss supplements contained illegal synthetic drugs.
research Social Interest Data as a Proxy for Off-Label Performance-Enhancing Drug Use: Implications and Clinical Considerations
Clinicians should use social and prescription data to track trends in performance-enhancing drug use.
research Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials
Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
research [RETRACTED] Folicrex: Know This First Before Buying Hair Regrowth Pills? v1
research Direct-to-consumer pharmaceutical services in dermatology: Ethical implications
Online skin care companies offer easy access to treatments but may have ethical issues like confirming patient identity, prescribing unproven therapies, and not fully explaining medication side effects. They should prioritize patient care over profit.
research Farmácia D'Arrábida, Vila Nova de Gaia
research Spotlight Commentary: Importance of dose redefining in the process of drug repurposing
Redefining drug dosages is crucial when repurposing them for new uses.
research Controle de qualidade em soluções de Minoxidil de farmácia magistral
Farmácias de manipulação precisam melhorar o controle de qualidade do Minoxidil.
research METHOD DEVELOPMENT AND VALIDATION OF UV-SPECTROPHOTOMETRIC ESTIMATION OF FINASTERIDE IN BULK AND PHARMACEUTICAL DOSAGE FORM
A reliable, cost-effective method was developed for accurately measuring finasteride in medicines.
research Long-Term Efficacy and Complete Scalp Hair Regrowth in Patients With Alopecia Areata Receiving Ritlecitinib 50 mg QD Up to 3 Years in the ALLEGRO Clinical Trial Program
Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.
research Optimisation of microstructured biodegradable finasteride formulation for depot parenteral application
Improved finasteride formula allows slow, sustained release and better absorption for patients.
research Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO ‐2b/3 and ALLEGRO ‐ LT Clinical Studies for Alopecia Areata
Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.
research Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
research Long-Term Efficacy of Ritlecitinib up to Month 24 From the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
Ritlecitinib is effective for long-term treatment of severe alopecia areata.
research Thrombotic risk minimization for D iane‐35 and generics
The use of Diane-35 and its generics significantly decreased in the Netherlands.
research In Silico Screening of DrugBank Compounds as Potential Inhibitors for Human Steroid 5α-Reductase 2 for Androgen-Related Diseases
Stiripentol shows promise as a potential treatment for androgen-related diseases but needs more testing.
research Liarozole—a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate
Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.
research Risk of rhabdomyolysis from 5-α reductase inhibitors
Starting 5-alpha reductase inhibitors does not significantly increase the risk of rhabdomyolysis in older men, but is linked to a higher risk of muscle conditions.
research Spontaneous cutaneous adverse drug reaction reports—An analysis of a 10‐year dataset in Singapore
In Singapore, most skin reactions to drugs were in females and Chinese, often caused by painkillers, antibiotics, and some other drugs, with serious cases linked to genetics.
research Compatibility of Cetirizine Hydrochloride, Dutasteride, Hydrocortisone Acetate, Nicotinamide, Progesterone, and Pyridoxine Hydrochloride in TrichoSolTM, A Natural Vehicle for Hair Solutions.
TrichoSolTM is safe for hair loss treatments with specific ingredient stability for up to 180 days.
research Finasteride/flibanserin
research Compatibility of 17-a-estradiol, Caffeine, Clobetasol Propionate, Finasteride Melatonin, Metronidazole, Spironolactone, Tretinoin, and Triamcinolone in Trichosol, a Natural Vehicle for Hair Solutions.
TrichoSol™ effectively stabilizes various hair treatment ingredients for different durations.
research ▼ Strontium ranelate discontinued
Strontium ranelate is no longer available for treatment.
research Alfuzosin/finasteride
research Alfuzosin/finasteride
research Fronteggiare l’inaffidabilità della letteratura da studi clinici
Public health decisions should rely on independent trials, not biased literature.